Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DOTA-TATE plus carboplatin, etoposide, and atezolizumab in newly diagnosed extensive-stage small cell lung cancer
NL-OMON61096Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in small cell lung cancer (SCLC) (2 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Adverse events and 1 more. Started Jul 2022; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61096.